Expert Insights

At 2023 ASCO Genitourinary Cancers Symposium, Gwenaelle Gravis, MD, presented a study evaluating the addition of apalutamide to active surveillance for patients with low to intermediate risk prostate cancer.

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.

Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.

Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.

At the 2023 ASCO GU Cancers Symposium, Andrew Katims, MD, presents results from an assessment of a ctDNA assay in node-positive muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.

At the 2023 ASCO Genitourinary Cancer Symposium, Aristotelis Bamias, MD, discusses overall survival results from the IMvigor130 study, evaluating atezolizumab monotherapy and platinum/gemcitabine chemotherapy among previously untreated...

Scott Tagawa, MD, presents results from a phase 2 study evaluating anti-PSMA salvage radio-immunotherapy for patients with high-risk non-metastatic castration-resistant prostate cancer.